Background As the population that is infected with the hepatitis C virus (HCV) ages, the
number of patients with decompensated cirrhosis is expected to increase. Methods We …

While for many years investigators had worked on highly effective direct-acting antiviral
agent (DAA) therapy, we are now encountering challenges on the appropriate timing of DAA …

DAA therapy is known to clear hepatitis C virus infection in patients with decompensated
cirrhosis (DC). However, the safety and benefits of DAA in DC remain unclear, especially …

Background/Aims Despite the high efficacy of direct-acting antivirals (DAAs), approximately
1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We …

Results Ninety-eight patients with CKD (42% stage 1 or 2 CKD and 58% stage 3 CKD) were
included. Mean age was 62 years old, 78% were men, and 65% were white. Additionally …

Background & Aims Sofosbuvir (SOF) based interferon-alfa free antiviral therapy has
become the treatment of choice for patients with chronic hepatitis C virus (HCV) infection …

Özet Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu,
dünyada 400 milyonun üzerinde kişide bulunan kronik hepatit B virusu (HBV) …

Background Few data are available on the virological and clinical outcomes of advanced
liver disease patients retreated after first-line DAA failure. Aim To evaluate DAA failure …

Hepatitis C virus (HCV) is a major cause of death from infectious disease and is still the
leading indication for liver transplantation in the United States and other Western countries …

The increasing effectiveness of oral regimens to treat hepatitis C has raised questions about
their role in treating patients with decompensated cirrhosis, especially those awaiting …